Engineered immune cells take aim at Hard-to-Treat leukemia

NCT ID NCT03766126

Terminated Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial tests a new therapy called CART123 for adults with acute myeloid leukemia (AML) that has not responded to standard treatments or has returned after treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD123. The study aims to see if this approach is safe and feasible to manufacture.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CART123 cells (engineered immune cells targeting CD123)
What this could lead to: If successful, this approach could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia.
What could go wrong: This is an early-phase trial with a small number of participants, so the treatment may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA, ADULT ACUTE MYELOID LEUKEMIA, IN RELAPSE ACUTE MYELOID LEUKEMIA, REFRACTORY

Contacts and locations

Show contact details

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.